ArticleFrontiers in immunology2026
Interaction between NKG2D and its ligands MICA/B activates the DAP12/SYK/p53/p21 axis to drive pulmonary fibrosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary fibrosis (PF) is a progressive, fatal interstitial lung disease with limited therapeutic options. Emerging evidence implicates immune-fibrotic crosstalk in PF pathogenesis, although the underlying molecular mechanisms remain poorly defined. While Natural Killer (NK) cells and their activating receptor NKG2D have been linked to fibrotic processes, their functional role in PF is unclear. This study investigates the NKG2D-DAP12-SYK-p53-p21 signaling axis as a potential driver of PF through immune-fibroblast interactions. Methods: We characterized the dynamic expression profile of NKG2D in pulmonary tissues derived from bleomycin (BLM)-induced model mice. Mechanistic investigations utilized AAV5-mediated NKG2D overexpression systems, coimmunoprecipitation assays, and functional pathway dissection to elucidate the DAP12-SYK-p53-p21 signaling axis. Therapeutic efficacy was evaluated via anti-NKG2D antibody treatment in murine PF models via histopathology, micro-CT imaging, and molecular profiling of fibrosis markers (collagen-I, fibronectin) and senescence-associated proteins (p-p53, p21). Results: Significant upregulation of NKG2D on pulmonary NK cells and its ligands on fibroblasts was detected in murine PF. AAV5-mediated NKG2D overexpression exacerbated BLM induced fibrosis, as evidenced by increased fibrosis scores alongside elevated levels of collagen-I and fibronectin. Mechanistically, NKG2D activation triggered DAP12-dependent SYK activation, leading to p53 phosphorylation and p21-mediated cellular senescence. Treatment with anti-NKG2D antibodies effectively mitigated disease progression by reducing collagen deposition while suppressing the downstream expression of SYK and p21. Conclusion: This study proposes that the NKG2D-DAP12-SYK-p53-p21 axis may represent a novel pathogenic pathway in PF, potentially linking immune dysregulation to cellular senescence. Therapeutic targeting of NKG2D could thus hold promise for the concurrent modulation of immune-fibrotic crosstalk and fibrotic progression, which might offer a new strategic direction for PF management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.